Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the U.S. and Mexico will be terminated as of June 30, 2016. Endo will continue to sell and distribute Natesto in the U.S. until the date of termination.
Natesto nasal gel, a CIII controlled substance, was initially approved in May 2014 and launched in March 2015. Acerus stated its plans to find a new Natesto partner in the U.S. to continue the supply.
Natesto nasal gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. These conditions include congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism.
Natesto nasal gel is available as a metered dose pump containing 60 actuations. Each pump delivers 5.5mg of testosterone in 0.122g gel.
For more information call (800) 462-3636 or visit Natesto.com.